KOD - NASDAQ
Kodiak Sciences Inc.
$33.87
-8.2%Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
At a Glance
Live SnapshotKodiak Sciences Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Kodiak Sciences Inc. Balance Sheet
KOD • NASDAQ
| Kodiak Sciences Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
209.9M | 168.1M | 285.5M | 190.4M | 731.5M | 944.4M | 211.8M | 88.3M | 1.4M | 9.6M | |
0.0 | 0.0 | 0.0 | 288.5M | 0.0 | 24.6M | 124.7M | 0.0 | 0.0 | 0.0 | |
209.9M | 168.1M | 285.5M | 478.9M | 731.5M | 969M | 348.2M | 88.3M | 1.4M | 9.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3M | 2.7M | 2.2M | 200K | 568K | |
5M | 3.9M | 3.8M | 7.1M | 3.3M | 0.0 | -11.7M | 2.2M | 0.0 | 0.0 | |
214.8M | 171.9M | 289.3M | 486M | 734.8M | 972M | 339.2M | 90.4M | 1.6M | 10.2M | |
NON-CURRENT ASSETS | ||||||||||
121.9M | 148.7M | 175M | 115.8M | 108.1M | 78.8M | 2.8M | 1.1M | 1.5M | 1.8M | |
0.0 | 6.2M | 6.3M | 6.3M | 6.3M | 0.0 | 11.7M | 140K | 140K | 140K | |
14.9M | 8.7M | 8.7M | 58.5M | 55M | 16.5M | 5.2M | 503K | 0.0 | 8K | |
136.7M | 163.6M | 190.1M | 180.6M | 169.4M | 95.3M | 19.6M | 1.7M | 1.6M | 1.9M | |
351.5M | 335.6M | 479.4M | 666.6M | 904.2M | 1.1B | 358.9M | 92.2M | 3.2M | 12.1M | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
12.9M | 3.9M | 13.6M | 9.1M | 12.4M | 8.6M | 2.6M | 1.1M | 3.4M | 1.1M | |
12.9M | 3.9M | 13.6M | 9.1M | 12.4M | 8.6M | 2.6M | 1.1M | 3.4M | 1.1M | |
0.0 | 11M | 6.1M | 6M | 6.2M | 20.4M | 3.1M | 3.8M | 5.8M | 1.3M | |
12.1M | 0.0 | 9.8M | 9.9M | 3.9M | 0.0 | 434K | 0.0 | 0.0 | 0.0 | |
0.0 | 10.6M | 0.0 | 0.0 | 0.0 | 2.4M | 434K | 0.0 | 108K | 82K | |
20.6M | 0.0 | 12.3M | 27.4M | 42.1M | 0.0 | 5.1M | 0.0 | -108K | 84K | |
45.5M | 25.6M | 41.7M | 52.5M | 64.7M | 31.4M | 11.7M | 4.8M | 9.2M | 2.5M | |
NON-CURRENT LIABILITIES | ||||||||||
47.1M | 0.0 | 100M | 100M | 99.9M | 0.0 | 0.0 | 0.0 | 10M | 0.0 | |
101.5M | 100M | 0.0 | 162K | 211K | 100.1M | 295K | 530K | 52.9M | 50.6M | |
148.6M | 159.7M | 171.9M | 178M | 176.2M | 175.2M | 1.8M | 530K | 62.8M | 50.7M | |
0.0 | 70.3M | 71.9M | 77.8M | 76.1M | 77.4M | 1.9M | 0.0 | 161K | 185K | |
194.2M | 185.3M | 213.6M | 230.5M | 240.9M | 206.6M | 13.5M | 5.4M | 72M | 53.2M | |
SHAREHOLDERS' EQUITY | ||||||||||
6K | 5K | 5K | 5K | 5K | 5K | 5K | 4K | 1K | 1K | |
0.0 | 1.5B | 1.4B | 1.3B | 1.2B | 1.2B | 503.5M | 197.6M | 584K | 303K | |
-1.6B | -1.3B | -1.2B | -892M | -558.2M | -291.2M | -158.1M | -110.8M | -69.3M | -41.4M | |
0.0 | 0.0 | 0.0 | -1.3M | 0.0 | 53K | 10K | 0.0 | 0.0 | 0.0 | |
1.7B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
157.4M | 150.3M | 265.8M | 436.2M | 663.3M | 860.8M | 345.4M | 86.8M | -68.7M | -41.1M | |
157.4M | 150.3M | 265.8M | 436.2M | 663.3M | 860.8M | 345.4M | 86.8M | -68.7M | -41.1M | |
SUMMARY | ||||||||||
351.5M | 335.6M | 479.4M | 666.6M | 904.2M | 1.1B | 358.9M | 92.2M | 3.2M | 12.1M | |
0.0 | 6.2M | 6.3M | 294.8M | 6.3M | 24.6M | 136.4M | 140K | 140K | 140K | |
59.2M | 70.3M | 181.6M | 187.7M | 179.9M | 77.4M | 1.9M | 0.0 | 10.1M | 185K | |
-150.7M | -97.7M | -103.9M | -2.7M | -551.6M | -867M | -209.9M | -88.3M | 8.7M | -9.4M | |
52,715,080 | 52,715,080 | 52,715,080 | 52,715,080 | 52,715,080 | 52,715,080 | 52,715,080 | 52,715,080 | 52,715,080 | 52,715,080 |
SEC Filings
KOD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 13, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your KOD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.